Clinical Trials Logo

Filter by:
NCT ID: NCT06145438 Recruiting - Endometriosis Ovary Clinical Trials

Comparing the Safety and Efficacy in the Use of Hormonal Therapy on Endometriosis Patients After Conservative Surgery

ENDOSafe
Start date: September 4, 2023
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to compare safety and efficacy in endometriosis patient after conservative surgery. The main question[s] it aims to answer are: 1. Health-related quality of life (HRQoL) 2. VAS score 3. Beta estradiol 4. TNF Alpha 5. Adnexal mass recurrence Participants will be randomized into 4 groups, each group will receive: 1. Leuprolide Acetate injection/month 2. Dienogest 2 mg/day 3. COC (mycrogynon)/day 4. DMPA injection 150mg/month Researcher will compare the efficacy and safety in the assigned group.

NCT ID: NCT06142461 Withdrawn - Vaccine Reaction Clinical Trials

Safety and Immunogenicity of HPV Vaccine Administered Intradermally and Intramuscularly Via Needle-Free Injection System

Start date: May 31, 2024
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate the safety and immunogenicity of an HPV Vaccine (Gardasil) delivered by intramuscular needle-free injection and intradermal needle-free injection. The main question it aims to answer is: - Is intramuscular and intradermal needle-free injection of Gardasil safe? - Does intramuscular and intradermal needle-free vaccination with Gardasil illicit an immune response? Participants will: - Receive Gardasil by intramuscular needle-free injection, intradermal needle-free injection, or needle and syringe injection. - Provide blood samples - Complete physical exams - Complete diaries

NCT ID: NCT06139679 Completed - Clinical trials for Atrial Septal Defect

Improvement In Left Ventricular Diameter After Closure Of ASD With Fenestrated Patch: A Cross-sectional Study

Start date: March 1, 2022
Phase:
Study type: Observational

Introduction: The presence of pulmonary hypertension (PH) in atrial septal defect (ASD) poses a clinical challenge on whether or not to close the defect. Closing the defect increases the risk of low cardiac output syndrome (LCOS), while leaving the defect open may eventually lead to irreparable shunt reversal, hypoxemia, and death. The implementation of a fenestrated patch may halt LCOS while adding volume to the left heart. Methods: this is an analytical observational study involving patients with ostium secundum defect with PH who were operated on in Dr. Soetomo Hospital between January 2017 and October 2021. The aim of this study is to evaluate the improvement in left ventricular size during both systole and diastole.

NCT ID: NCT06138262 Completed - Health Education Clinical Trials

Preconception Nutrition Education Intervention for Prospective Brides

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

This research focuses on the importance of preconception health care. In this research, an intervention was carried out providing health education regarding preconception nutritional preparation. Research methods used is a Quasi Experiment with the Non Equivalent Control Group method. Example used in this research were 100 prospective brides and grooms in Indonesia. The intervention group will be provided with education through a preconception nutrition education module and the brides health card, and the control group was given education using the brides health leaflet.

NCT ID: NCT06137937 Completed - Clinical trials for Chronic Kidney Diseases

Intradialytic Aerobic Exercise in CKD Patient

Start date: November 1, 2023
Phase: N/A
Study type: Interventional

Intradialytic aerobic exercise is not effective in increasing hemodialysis adequacy but is effective in improving physical performance in twice-weekly hemodialysis patients.

NCT ID: NCT06134427 Completed - Military Activity Clinical Trials

Body Fat Percentage Prediction Model After Basic Combat Training on Army Candidate in Indonesia

Start date: May 17, 2023
Phase: N/A
Study type: Interventional

This research is a quantitative study using the Pre-Experimental Model One-Group Pretest-Posttest Design with total sampling from the Republic of Indonesia Defense University batch 4 cadets that fullfiled criteria. The intervention is 12 weeks basic combat training (only one group), a compulsory program for cadets.

NCT ID: NCT06131554 Recruiting - Clinical trials for Meningococcal Meningitis

A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years

Start date: March 20, 2024
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized, double-blinded, positive controlled study to evaluate the lot-to-lot consistency, immunogenicity and safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in adults aged 18 to 55 years. Subjects will be randomized to receive investigational Lot 1, Lot 2, Lot 3 vaccine or control vaccine in a 1:1:1:1 ratio, with the subjects in experimental group randomly and equally assigned to three different batches of MCV4 for single-dose vaccination.

NCT ID: NCT06128694 Recruiting - Cancer, Lung Clinical Trials

Effect of NUTRICAN to Improve Nutritional Status in Cancer Patients

Start date: August 1, 2023
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to evaluate the efficacy oral nutrition supplement (ONS) in malnutrition/high risk malnutrition cancer patients. The main questions it aims to answer: 1. Are there differences in knowledge, attitude and behaviour scores in cancer patients who receive cancer-specific ONS compared to those who do not receive cancer-specific ONS? 2. Is there a difference in nutritional status as assessed by average body weight, body mass index (BMI), haemoglobin (Hb), and albumin levels in cancer patients who receive cancer-specific ONS compared to those who do not receive cancer-specific ONS?

NCT ID: NCT06127225 Recruiting - Clinical trials for Non-Alcoholic Fatty Liver Disease (NAFLD)

Proliverenol Supplementation for Non-Alcoholic Fatty Liver Disease (NAFLD)

Start date: April 28, 2023
Phase: Phase 2
Study type: Interventional

This is a 4-arm, prospective, randomized, double-blind, double-dummy, and placebo-controlled clinical study comparing Proliverenol at a dose of 500 mg twice daily; Proliverenol at a dose of 1000 mg once daily; Proliverenol at a dose of 1000 mg twice daily; and Placebo two caplets daily for a 12-week course of therapy. Proliverenol is a bioactive fraction derived from the dried fruit of Phaleria macrocarpa (Scheff.) Boerl (Thymelaeaceae). Proliverenol possesses a hepatoprotective activity via anti-inflammation, DNA repairing, and the antiapoptosis properties. Pre-clinical study of Proliverenol showed that it exerted the hepatoprotective activity through increasing cell survival via: 1) up-regulation of DNA repair enzyme; 2) down-regulation of NF-kB, TNFα and caspase-8 expressions, to prevent ALT leakage in HepG2 cells. Proliverenol repressed ALT expression, which could also be significantly important as possible alternative mechanism for increased blood transaminase activities. Caspase-8 pathway seemed to be involved in the molecular pathway rather than directly inducing mitochondrial damage. Taken together, ethanol induced apoptosis through NF-kB-TNFα-caspase-8 pathway, and Proliverenol protected the cells from the toxicity conditions.

NCT ID: NCT06127212 Completed - Healthy Clinical Trials

Bioequivalence Study of Dapagliflozin 10 mg Film-coated Tablets

Start date: March 8, 2023
Phase: N/A
Study type: Interventional

The study was an open-label, randomized, single-dose, two-period, two-sequence, two-day crossover study, conducted to find out whether the dapagliflozin 10 mg film-coated tablet produced by PT Dexa Medica (test drug) was bioequivalent to the reference drug (Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia), under fasting condition with a five days wash-out period, involving 24 healthy adult male and female subjects.